Podcast

Breaking Barriers: An Egyptian Immigrant's Journey with ALL

Author(s):

Kristie L. Kahl

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bishoy Tadros, who went on to break barriers after he was diagnosed with acute lymphoblastic leukemia at the age of 3 and immigrated to the United States from Egypt to receive treatment.

At the age of 3, Bishoy Tadros received a diagnosis of acute lymphoblastic leukemia and immigrated to the United States with him family to receive treatment.

After moving to Los Angeles and then to Long Island, New York, Tadros underwent varios aggressive surgeries and entered remission on his 13th birthday.

However, it wasn’t until 2017 that he was inspired to share his story. He pushed away from his comfort zone, entering to run the New York City Marathon and raising money for the Leukemia and Lymphoma Society — all of which helped him to realize the power of his personal story.

Tadros wrote a memoir, titled “Break Barriers,” to help individuals learn that setbacks are never instilled to define oneself, and that patience, perspective and purpose are key.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Illustration of blood cells.
November 20th 2024

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

Ryan Scott
The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of an orange background with the words "FDA Approval, developing story."
November 8th 2024

FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL

Darlene Dobkowski, MA
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.
"FDA" text.
November 1st 2024

Oncology Drugs Approved by the FDA in October 2024

Darlene Dobkowski, MA
During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.